Showing 6231-6240 of 19384 results for "".
Evaluating AR1001: A Phase 3 Trial in Early Alzheimer’s Disease
https://reachmd.com/programs/neurofrontiers/ar1001-phase-3-trial-alzheimers/40005/AR1001 is a novel oral therapy being evaluated in a large, global, phase 3 trial for mild cognitive impairment and mild dementia due to Alzheimer's disease. Tune in to hear Dr. Sharon Sha discuss the trial’s unique biomarker-agnostic design, participant demographics, and its potential to demonstrateTiming Meningococcal Vaccines in gMG: Challenges and Considerations
https://reachmd.com/programs/neurofrontiers/timing-meningococcal-vaccines-in-gmg-challenges-and-considerations/32861/Evolving vaccination guidelines and varying clinical opinions have created uncertainty around the timing of meningococcal immunization in patients with generalized myasthenia gravis (gMG). Tune in to hear Dr. Michael Weiss, who spoke with ReachMD at the AANEM 2025 Annual Meeting, discuss how he balaOCT Biomarkers as Predictors of Treatment Response in RVO-Related Macular Edema
https://reachmd.com/programs/eye-on-ocular-health/oct-biomarkers-as-predictors-of-treatment-response-in-rvo-related-macular-edema/37664/Retinal vein occlusion (RVO) is a leading cause of sudden vision loss, often complicated by macular edema that affects patient outcomes. While treatment options like anti-vascular endothelial growth factor agents and corticosteroid implants exist, predicting response remains a challenge. Hear Dr. MiThe Future of Precision Medicine in COPD Care: Biomarkers, AI, and Multimodal Data
https://reachmd.com/programs/frontlines-copd/the-future-of-precision-medicine-in-copd-care-biomarkers-ai-and-multimodal-data/36471/Precision medicine in chronic obstructive pulmonary disease (COPD) care is no longer a distant goal; it’s already taking shape through examples like using eosinophil counts to guide dupilumab therapy. But as Dr. Matthew Moll explains, this is just the beginning. Tune in to hear Dr. Moll talk about hOptimizing DMD Care Through Multidisciplinary Collaboration
https://reachmd.com/programs/neurofrontiers/optimizing-dmd-care-through-multidisciplinary-collaboration/35683/Due to its multisystemic nature, Duchenne muscular dystrophy (DMD) demands a collaborative, multidisciplinary approach. That’s why Dr. Kaitlin Batley joins us to share her insights on the essential role of integrated care teams—spanning cardiology, pulmonology, endocrinology, rehabilitation, palliatTargeting Senescent Cells
https://reachmd.com/series/c-suite-chats/targeting-senescent-cells/35960/Rubedo Life Science CEO Frederick Beddingfield III, MD, PhD, FAAD, FACMS, talks about the importance of addressing aging and senescence, and his company's investigational drug that targets pathological senescent cells and surrounding tissues that drive inflammaging and chronic degenerative diseasesTherapeutic Advances and Fighting for Authorizations
https://reachmd.com/programs/practical-dermatology/therapeutic-advances-and-fighting-for-authorizations/35890/Joel L. Cohen, MD, FAAD, and Leon Kircik, MD, FAAD, discuss the latest developments in psoriasis and atopic dermatitis, as well as the challenges involved with fighting for prior authorizations for the best therapies, at Music City SCALE 2025.Recognizing Asthma-COPD Overlap: Clinical Clues and Diagnostic Strategies
https://reachmd.com/programs/frontlines-copd/recognizing-asthma-copd-overlap-clinical-clues-and-diagnostic-strategies/35541/Since asthma-COPD overlap syndrome combines features of two distinct respiratory diseases, there’s no single diagnostic test available. And so clinicians must integrate biomarkers and testing strategies from both disease frameworks to properly assess these complex cases. Here to share key strategiesScalp Psoriasis Treatment: Examining Deucravacitinib’s Efficacy and Safety
https://reachmd.com/programs/frontlines-psoriasis/scalp-psoriasis-treatment-examining-deucravacitinibs-efficacy-and-safety/32429/Dive into the efficacy and safety of deucravacitinib, a selective TYK2 inhibitor that has shown favorable outcomes in treating scalp psoriasis.Transforming Schizophrenia Treatment: Advances in Medication and Therapy
https://reachmd.com/programs/neurofrontiers/transforming-schizophrenia-treatment-advances-in-medication-and-therapy/27073/Dive into emerging schizophrenia treatments, including promising new medications.